With one of the higher series A rounds for 2023, the newly launched Aiolos Bio Inc. pulled in $245 million to advance its lead product, AIO-001, an anti-thymic stromal lymphopoietin monoclonal antibody set to enter a phase II trial for moderate to severe asthma.